ascopubs.org

Tislelizumab in combination with abiraterone/enzalutamide for metastatic castration-resistant prostate cancer with intraductal adenocarcinoma of the prostate after progression ...

Bipolar androgen therapy (BAT) for nonmetastatic castration-resistant prostate (nmCRPC) cancer progressing on darolutamide: Working Out M0 BAT (WOMBAT; ANZUP 2201). This is an ASCO Meeting Abstract ...
Nature

Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey

Novel therapies for metastatic castration-resistant prostate cancer (mCRPC) have improved patient outcomes. However, there is uncertainty on the optimal selection of therapeutic agents for subsequent ...
ascopubs.org

Surgical Castration as an Alternative to Improve Systemic Treatment for Advanced Prostate Cancer: A Window of Opportunity for Developing Countries

Toward a Framework to Assess the Financial and Economic Burden of Cervical Cancer in Low- and Middle-Income Countries: A Systematic Review The Brazilian Public Health System (BPHS) serves ...
Nature

Screening and validation of key genes involved in castration-resistant prostate cancer based on transcriptomics sequencing

Prostate cancer is one of the most common malignant tumors occurring in the male reproductive system. Androgen deprivation therapy (ADT) is the primary treatment for prostate cancer. However, ...
Cure Today

Xtandi Offers Small Benefits Over Zytiga in Advanced Prostate Cancer

Researchers have compared Xtandi and Zytiga head-to-head in the treatment of metastatic castration-resistant prostate cancer. Among patients with metastatic castration-resistant prostate cancer (mCRPC ...
Cure Today

FDA Grants Fast Track Designation to HLD-0915 in Prostate Cancer

HLD-0915 has received FDA fast track designation for mCRPC, expediting its development and review process to address unmet medical needs. Halda Therapeutics is conducting a phase 1/2 clinical trial to ...